Tag Archives: Insys Therapeutics

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.

This New Study Should Encourage Marijuana Stock Investors

This New Study Should Encourage Marijuana Stock Investors

The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.

Investors Are Betting Big Against Marijuana Stock Insys Therapeutics

Investors Are Betting Big Against Marijuana Stock Insys Therapeutics

As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short. That’s 44% of the marijuana stock’s float. Investors have clearly bet big against Insys, anticipating that the stock will sink.

5 Drug-Developing Marijuana Stocks You Need to Know

5 Drug-Developing Marijuana Stocks You Need to Know

Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.

How Big Could the Opportunity Be for Marijuana Stocks in California?

How Big Could the Opportunity Be for Marijuana Stocks in California?

The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.

Defendant in Opioid Kickback Case Claims Right to Smoke Pot

Defendant in Opioid Kickback Case Claims Right to Smoke Pot

A U.S. ex-pharmaceutical sales representative accused of paying kickbacks to induce doctors to write prescriptions for an opioid drug is asserting he has a constitutional right to continue smoking marijuana so he can remain clear-headed for his defense. “It is a very creative defense,” said Keith Stroup, the legal counsel and founder of NORML, a

Arizona

Arizona Anti-Marijuana Group Gets Big Donation From Opiate Maker

An Arizona opiate maker has given the largest donation to a group working to keep marijuana illegal in the state, according to an article at Tuscon.com. Drug manufacturer Insys Therapeutics made a $500,000 donation to Arizonans for Responsible Drug Policy, according to information from the Arizona Secretary of State’s office.

Insys Therapeutics

Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients

PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.

market

Are Cannabis Stocks Riding a Market Wave?

In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.

stock forecast

What the 5 Largest Cannabis Stocks Can Tell Us

The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.


Top